Early Evaluation of Cancer Response by a New Functional Biomarker: Apparent Diffusion Coefficient
Early Evaluation of Cancer Response by a New Functional Biomarker: Apparent Diffusion Coefficient
复制标题
通过新的功能生物标志物对癌症反应的早期评估：表观扩散系数
DOI：
10.2214/ajr.10.4912
复制
发表时间：
2011-07-01
影响因子：
5
通讯作者：
Zhang, Xiao-Peng
中科院分区：
文献类型：
--
作者：
Sun, Ying-Shi;Cui, Yong;Zhang, Xiao-Peng
目标。本文的目的是探讨表观扩散系数（ADC）是否可以作为一种通用的生物标志物来评估不同肿瘤的疗效。研究对象和方法。21例肺癌患者、12例食管癌患者、19例肝转移患者、24例胃癌患者、26例直肠癌患者被纳入研究。采用重复测量方差分析，分析不同肿瘤治疗后ADC的百分比变化及应答和无应答病变大小的变化。不同肿瘤间ADC变化百分比差异无统计学意义（F = 1.57; p = 0.192）。有应答与无应答肿瘤的ADC百分比变化差异明显（F = 21.62, p < 0.001），且在治疗开始后的各个时间点（早期时间点，F = 19.75, p < 0.001；中期时间点，F = 11.23, p = 0.001；晚期时间点，F = 15.98, p < 0.001）均有显著性差异。治疗后反应性肿瘤和无反应性肿瘤的百分比变化差异有统计学意义（F = 19.38; p < 0.001）。但在治疗后早期时间点，差异无统计学意义（F = 0.02; p = 0.894）。ADC的变化与五种肿瘤的治疗反应相关，但与肿瘤的位置无关。治疗期间ADC的早期升高表明对治疗反应良好。ADC变化是一种很有前途的生物标志物，可以在早期阶段检测治疗反应，可以广泛应用。
OBJECTIVE. The purpose of this article is to investigate whether apparent diffusion coefficient (ADC) might be used as a universal biomarker for response evaluation in different tumors.SUBJECTS AND METHODS. Twenty-one patients with lung cancer, 12 patients with esophageal cancer, 19 patients with liver metastases, 24 patients with gastric cancer, and 26 patients with rectal cancer were recruited to the study. Percentage changes in the ADC and changes in the size of responding and nonresponding lesions of different tumors after treatment were analyzed using repeated measures analysis of variance.RESULTS. There was no significant difference among the percentage ADC changes of different tumors (F = 1.57; p = 0.192). Clear differences were seen in the percentage ADC changes between responding and nonresponding tumors (F = 21.62; p < 0.001), which were significant at every time point after the start of treatment (early time point, F = 19.75 and p < 0.001; middle time point, F = 11.23 and p = 0.001; and later time point, F = 15.98 and p < 0.001). The percentage size changes after treatment between responding and nonresponding tumors were significantly different (F = 19.38; p < 0.001). However, at the early time point after treatment, the difference was not statistically significant (F = 0.02; p = 0.894).CONCLUSION. The ADC changes correlated with treatment response in five types of body tumor but were independent of the tumor's location. Early increases in ADC during treatment indicate good response to treatment. ADC change is a promising biomarker for detecting therapeutic responses at an early stage that could be widely used.